EC

EcoR1 Capital Portfolio holdings

AUM $2.06B Turnover 46.34%
1-Year Est. Return 215.32%
This Fund
S&P 500
This Quarter Est. Return
+30.44%
1 Year Est. Return
+215.32%
3 Year Est. Return
+310.3%
5 Year Est. Return
+497.45%
10 Year Est. Return
+14,692.23%
AUM
$318M
AUM Growth
+$98.7M
Cap. Flow
+$13.5M
Cap. Flow %
4.23%
Top 10 Hldgs %
67.71%
Holding
36
New
11
Increased
7
Reduced
7
Closed
5
Avg Time Held Equity + Options
0.4 years
Top 10 Avg Time Held Equity + Options
0.3 years
Top 20 Avg Time Held Equity + Options
0.5 years
Avg Time Held Equity only
0.5 years
Top 10 Avg Time Held Equity only
0.4 years
Top 20 Avg Time Held Equity only
0.6 years

Top Buys

Rank Stock Value
1
KURA icon
Kura Oncology
KURA
+$19.3M
2
FPRX
Five Prime Therapeutics, Inc.
FPRX
+$19.1M
3
CYTK icon
Cytokinetics
CYTK
+$13.9M
4
IRWD icon
Ironwood Pharmaceuticals
IRWD
+$9.48M
5
LKFT icon
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$8.55M

Top Sells

Rank Stock Value
1
ATRA icon
Atara Biotherapeutics
ATRA
+$25.3M
2
EPZM
Epizyme, Inc
EPZM
+$11.8M
3
KITE
Kite Pharma, Inc.
KITE
+$8.12M
4
CASC
Cascadian Therapeutics, Inc.
CASC
+$2.58M
5
OREX
Orexigen Therapeutics, Inc.
OREX
+$1.98M

Sector Composition

Rank Sector Weight
1 Healthcare 77.71%
2 Miscellaneous 22.29%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
KYNB icon
1
Kyntra Bio
KYNB
$23.4M
$37.1M 11.64%
48,659
-557
-1% -$370K
2014 Q4
4 quarters
FPRX
2
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$29.8M 9.37%
719,000
+570,000
+383% +$19.1M
2015 Q3
1 quarter
JAZZ icon
3
CALL
Jazz Pharmaceuticals
JAZZ
$13.8B
$26.6M 8.35%
+189,200
New +$26.2M
2015 Q4
0 quarters
TVTX icon
4
Travere Therapeutics
TVTX
$5.06B
$23.6M 7.42%
1,224,384
+216,724
+22% +$4.33M
2015 Q1
3 quarters
KURA icon
5
Kura Oncology
KURA
$862M
$20.6M 6.46%
+2,450,000
New +$19.3M
2015 Q4
0 quarters
ASMB icon
6
Assembly Biosciences
ASMB
$425M
$15.8M 4.95%
174,859
+17,603
+11% +$1.92M
2014 Q4
4 quarters
CYTK icon
7
Cytokinetics
CYTK
$8.87B
$14.8M 4.66%
+1,418,700
New +$13.9M
2015 Q4
0 quarters
BHC icon
8
CALL
Bausch Health
BHC
$2.21B
$12.9M 4.04%
126,500
+125,235
+9,900% +$14.1M
2015 Q3
1 quarter
COLL icon
9
Collegium Pharmaceutical
COLL
$726M
$12.8M 4.02%
465,118
– –
2015 Q2
2 quarters
EPZM
10
DELISTED
Epizyme, Inc
EPZM
$11.2M 3.52%
698,900
-793,800
-53% -$11.8M
2015 Q1
3 quarters
LKFT icon
11
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.92B
$10.5M 3.31%
+167,361
New +$8.55M
2015 Q4
0 quarters
KITE
12
DELISTED
Kite Pharma, Inc.
KITE
$10.2M 3.21%
166,000
-115,400
-41% -$8.12M
2014 Q4
4 quarters
DCOY icon
13
Decoy Therapeutics
DCOY
$773K
$9.9M 3.11%
1
– –
2015 Q1
3 quarters
IRWD icon
14
Ironwood Pharmaceuticals
IRWD
$595M
$9.52M 2.99%
+980,908
New +$9.48M
2015 Q4
0 quarters
NBRV
15
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$7.93M 2.49%
3,355
+13
+0.4% +$31.7K
2015 Q3
1 quarter
ATYR icon
16
aTyr Pharma
ATYR
$18.2M
$7.77M 2.44%
56,462
-3,571
-6% -$508K
2015 Q2
2 quarters
KIN
17
DELISTED
Kindred Biosciences, Inc.
KIN
$4.87M 1.53%
1,432,765
+109,334
+8% +$507K
2014 Q4
4 quarters
TVTX icon
18
CALL
Travere Therapeutics
TVTX
$5.06B
$4.71M 1.48%
+244,100
New +$4.88M
2015 Q4
0 quarters
EIGR
19
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$4.18M 1.31%
6,318
– –
2015 Q2
2 quarters
TPST icon
20
Tempest Therapeutics
TPST
$10.9M
$4.15M 1.3%
+145
New +$4.78M
2015 Q4
0 quarters
GNVC
21
DELISTED
GenVec, Inc.
GNVC
$3.53M 1.11%
192,091
-6,550
-3% -$125K
2014 Q4
4 quarters
CALA
22
DELISTED
Calithera Biosciences, Inc
CALA
$3.18M 1%
20,774
– –
2014 Q4
4 quarters
CYTK icon
23
CALL
Cytokinetics
CYTK
$8.87B
$2.98M 0.94%
+284,600
New +$2.79M
2015 Q4
0 quarters
LRMR icon
24
Larimar Therapeutics
LRMR
$230M
$2.32M 0.73%
+30,750
New +$4.94M
2015 Q4
0 quarters
FWP
25
DELISTED
Forward Pharma A/S American Depositary Shares
FWP
$1.9M 0.6%
14,288
-283
-2% -$45.4K
2014 Q4
4 quarters
1
2

Similar funds

RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
ST
Spinnaker Trust Portland, Maine $2.06B AUM 24.94% 1-Year Est. Return
ABTD
Arvest Bank Trust Division Dewey, Oklahoma $2.05B AUM 30.62% 1-Year Est. Return
CFA
Capstone Financial Advisors Downers Grove, Illinois $2.05B AUM 19.29% 1-Year Est. Return
DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $2.05B AUM 30.99% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $2.05B AUM 4.29% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $2.05B AUM 18.42% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $2.05B AUM 0.32% 1-Year Est. Return

EcoR1 Capital's Q4 2015 Portfolio in Review

As of Q4 2015, EcoR1 Capital held 36 positions worth $318M, up 45% from $220M the previous quarter. Its ten largest holdings account for 68% of the portfolio.

EcoR1 Capital deployed $13.5M of net new capital in Q4 2015, opening 11 new positions and adding to 7 existing holdings. Its largest new stake was Kura Oncology: 2,450,000 shares worth $20.6M.

By sector, the portfolio is most concentrated in Healthcare at 78% of assets, down from 88% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Epizyme, Inc, an estimated $11.8M trimmed.

  • EcoR1 Capital's largest Q4 2015 buy was Kura Oncology: 2,450,000 shares worth $20.6M.
  • EcoR1 Capital added most to Five Prime Therapeutics, Inc. in Q4 2015, an estimated $19.1M increase.
  • EcoR1 Capital's biggest Q4 2015 reduction was Epizyme, Inc, cutting an estimated $11.8M.
  • EcoR1 Capital fully exited Atara Biotherapeutics in Q4 2015, selling an estimated $25.3M.
  • EcoR1 Capital's ten largest holdings make up 68% of its $318M portfolio in Q4 2015.
  • EcoR1 Capital opened 11 new positions and closed 5 in Q4 2015.
  • EcoR1 Capital's portfolio value rose 45% quarter-over-quarter to $318M.

Based on EcoR1 Capital's 13F filing for Q4 2015, filed 16 Feb 2016.